<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507947</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1332</org_study_id>
    <nct_id>NCT02507947</nct_id>
  </id_info>
  <brief_title>SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access</brief_title>
  <official_title>SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPECTAmel is a standardized, quality-assured molecular screening platform for tumor&#xD;
      characterization and storage of human biological material (HBM) for the purpose of&#xD;
      integrating new biomarkers into clinical trials and optimizing access of patients to&#xD;
      therapeutic biomarker-driven clinical trials. HBM and clinical/pathological data are&#xD;
      collected from consenting patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study closed&#xD;
  </why_stopped>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of screened patients</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of downstream clinical trials;</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients enrolled in the downstream therapeutic trials</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of exploratory/future research projects</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Melanoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE block of tumor tissue, blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pathologically confirmed melanoma of any stage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed melanoma of any stage (the steering committee will decide on&#xD;
             which stage to include at any particular time point during this trial, this will be&#xD;
             communicated appropriately to all participating sites)&#xD;
&#xD;
          -  Mandatory availability of adequate human biological material (HBM): FFPE tissue sample&#xD;
             from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary&#xD;
             surgery/biopsy; minimal amount requested is detailed in the HBM guidelines; if&#xD;
             feasible, inclusion of samples taken at any recurrence diagnosed during follow-up is&#xD;
             strongly encouraged but optional;&#xD;
&#xD;
          -  Age â‰¥ 18 years;&#xD;
&#xD;
          -  At least three months life-expectancy;&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP and national/local regulations;&#xD;
&#xD;
          -  Absence of any active malignancy, except pT1-2 prostatic cancer Gleason score &lt; 6, or&#xD;
             carcinoma in situ of the cervix, in the 5 years before study entry;&#xD;
&#xD;
          -  Absence of exclusion criteria like active hepatitis B/C or HIV, second malignancies,&#xD;
             no severe organ dysfunction or other comorbidities that may prevent inclusion into&#xD;
             clinical trials.&#xD;
&#xD;
          -  Central confirmation of human biological material (HBM) adequacy for step 2:&#xD;
&#xD;
          -  Centrally performed confirmation of tumor tissue adequacy in terms of quality/&#xD;
             quantity for central screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active hepatitis B/C or HIV&#xD;
&#xD;
          -  second malignancies&#xD;
&#xD;
          -  severe organ dysfunction or other comorbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Robert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

